Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
20/11/2025 21:39
Nov 20 (Reuters) - Inhibikase Therapeutics Inc IKT.O: INHIBIKASE THERAPEUTICS ADVANCING IKT-001 TO GLOBAL PHASE 3 STUDY IN PULMONARY ARTERIAL HYPERTENSION INHIBIKASE THERAPEUTICS INC - IMPROVE-PAH PHASE 3 STUDY EXPECTED TO START IN Q1 2026 Source text: ID:nGNX3cv1cC Further company coverage: IKT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary